» Articles » PMID: 29346310

AR Signaling in Human Malignancies: Prostate Cancer and Beyond

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2018 Jan 19
PMID 29346310
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

The notion that androgens and androgen receptor (AR) signaling are the hallmarks of prostate cancer oncogenesis and disease progression is generally well accepted. What is more poorly understood is the role of AR signaling in other human malignancies. This special issue of initially reviews the role of AR in advanced prostate cancer, and then explores the potential importance of AR signaling in other epithelial malignancies. The first few articles focus on the use of novel AR-targeting therapies in castration-resistant prostate cancer and the mechanisms of resistance to novel antiandrogens, and they also outline the interaction between AR and other cellular pathways, including PI3 kinase signaling, transcriptional regulation, angiogenesis, stromal factors, Wnt signaling, and epigenetic regulation in prostate cancer. The next several articles review the possible role of androgens and AR signaling in breast cancer, bladder cancer, salivary gland cancer, and hepatocellular carcinoma, as well as the potential treatment implications of using antiandrogen therapies in these non-prostatic malignancies.

Citing Articles

Dysregulated LINC01133 expression in laryngeal carcinoma: Prognostic implications and predicted ceRNA interactome.

Razipour M, Jamali Z, Sohrabpour S, Heidari F, Lotfi M, Ghadami E Mol Biol Res Commun. 2025; 14(1):93-107.

PMID: 39744510 PMC: 11624609. DOI: 10.22099/mbrc.2024.50390.1996.


Sex difference in human diseases: mechanistic insights and clinical implications.

Shi Y, Ma J, Li S, Liu C, Liu Y, Chen J Signal Transduct Target Ther. 2024; 9(1):238.

PMID: 39256355 PMC: 11387494. DOI: 10.1038/s41392-024-01929-7.


Androgen receptor activity inversely correlates with immune cell infiltration and immunotherapy response across multiple cancer lineages.

Hu Y, Zhao F, Graff J, Chen C, Zhao X, Thomas G bioRxiv. 2024; .

PMID: 38798471 PMC: 11118439. DOI: 10.1101/2024.05.08.593181.


Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study.

Kim J, Bae G, Jung J, Noh T World J Mens Health. 2024; 43(1):123-133.

PMID: 38606859 PMC: 11704168. DOI: 10.5534/wjmh.230237.


Sex-specific outcomes in cancer therapy: the central role of hormones.

Bakhshi P, Ho J, Zanganeh S Front Med Technol. 2024; 6:1320690.

PMID: 38362126 PMC: 10867131. DOI: 10.3389/fmedt.2024.1320690.


References
1.
Cucchiara V, Yang J, Mirone V, Gao A, Rosenfeld M, Evans C . Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy. Cancers (Basel). 2017; 9(1). PMC: 5295780. DOI: 10.3390/cancers9010009. View

2.
Schweizer M, Yu E . AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. Cancers (Basel). 2017; 9(1). PMC: 5295778. DOI: 10.3390/cancers9010007. View

3.
Asano Y, Kashiwagi S, Goto W, Tanaka S, Morisaki T, Takashima T . Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer. Cancers (Basel). 2017; 9(1). PMC: 5295775. DOI: 10.3390/cancers9010004. View

4.
Leach D, Buchanan G . Stromal Androgen Receptor in Prostate Cancer Development and Progression. Cancers (Basel). 2017; 9(1). PMC: 5295781. DOI: 10.3390/cancers9010010. View

5.
Eisermann K, Fraizer G . The Androgen Receptor and VEGF: Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer. Cancers (Basel). 2017; 9(4). PMC: 5406707. DOI: 10.3390/cancers9040032. View